Back to Journals » International Journal of Nanomedicine » Volume 15

G250 Antigen-Targeting Drug-Loaded Nanobubbles Combined with Ultrasound Targeted Nanobubble Destruction: A Potential Novel Treatment for Renal Cell Carcinoma

Authors Yu Z, Wang Y, Xu D, Zhu L, Hu M, Liu Q, Lan W, Jiang J, Wang L

Received 14 September 2019

Accepted for publication 16 December 2019

Published 8 January 2020 Volume 2020:15 Pages 81—95


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Linlin Sun

Zhiping Yu,1 Yixuan Wang,2 Dan Xu,3 Lianhua Zhu,3 Ming Hu,1 Qiuli Liu,1 Weihua Lan,1 Jun Jiang,1 Luofu Wang1

1Department of Urology, Daping Hospital, Army Medical University, Chongqing, People’s Republic of China; 2The First Clinical College, Chongqing Medical University, Chongqing, People’s Republic of China; 3Department of Ultrasound, Southwest Hospital, Army Medical University, Chongqing, People’s Republic of China

Correspondence: Luofu Wang
Department of Urology, Daping Hospital, No. 10 Changjiangzhilu Road, Yuzhong District, Chongqing 400042, People’s Republic of China
Tel +86-13320350708
Fax +86-23-68757947

Purpose: We intended to design G250 antigen-targeting temsirolimus-loaded nanobubbles (G250-TNBs) based on the targeted drug delivery system and to combine G250-TNBs with ultrasound targeted nanobubble destruction (UTND) to achieve a synergistic treatment for renal cell carcinoma (RCC).
Methods: The filming-rehydration method was combined with mechanical shock and electrostatic interactions to prepare temsirolimus-loaded nanobubbles (TNBs). G250-TNBs were prepared by attaching anti-G250 nanobodies to the surface of TNBs using the biotin-streptavidin-bridge method. The ability of G250-TNBs to target the G250 antigen of RCC cells and the synergistic efficacy of G250-TNBs and UTND in the treatment of RCC were assessed.
Results: The average diameter of the prepared G250-TNBs was 368.7 ± 43.4 nm, the encapsulation efficiency was 68.59% ± 5.43%, and the loading efficiency was 5.23% ± 0.91%. In vitro experiments showed that the affinity of G250-TNBs to the human RCC 786-O cells was significantly higher than that of TNBs (P <0.05), and the inhibitory effect on 786-O cell proliferation and the induction of 786-O cell apoptosis was significantly enhanced in the group treated with G250-TNBs and UTND (G250-TNBs+ UTND group) compared with the other groups (P <0.05). In a nude mouse xenograft model, compared with TNBs, G250-TNBs could target the transplanted tumors and thus significantly enhance the ultrasound imaging of the tumors. Compared with all other groups, the G250-TNBs+UTND group exhibited a significantly lower tumor volume, a higher tumor growth inhibition rate, and a higher apoptosis index (P <0.05).
Conclusion: The combined G250-TNBs and UTND treatment can deliver anti-tumor drugs to local areas of RCC, increase the local effective drug concentration, and enhance anti-tumor efficacy, thus providing a potential novel method for targeted therapy of RCC.

Keywords: nanobubble, G250 antigen, nanobody, targeted drug delivery system, renal cell carcinoma, temsirolimus

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]